Celltrion opens new UK headquarters in Uxbridge, UK
June 17, 2025 – Clinical Trials, Drug Discovery, Manufacturing and Packing, Other, Pharmaceutical – Celltrion, biopharmaceutical, biosimilars, monoclonal antibodies
New office located in the heart of Uxbridge underscores Celltrion’s long-term business commitment in the UK
17 June 2025 — London, UK — Celltrion UK has officially opened its new UK headquarters
at the Charter Building in Uxbridge, UK, reinforcing the company’s dedication to long-term growth
and partnership in the UK market.
The opening ceremony was attended by Hyoung-Ki Kim, CEO and Vice Chairman at Celltrion,
Rosalind Campion, Director of the Office for Life Sciences and Mark Samuels, Chief Executive of
Medicines UK, and the British Biosimilars Association. The event was marked with a ribbon cutting
ceremony.
Strategically located in the heart of Uxbridge, the new office will serve as Celltrion UK’s central hub
for UK operations. This move places Celltrion among a growing list of life sciences companies
including Regeneron, Amgen, Gilead Sciences, Daiichi Sankyo, that have established presence in
Uxbridge – emerging as a leading hub for biotechnology and pharmaceutical innovation.
Speaking at the opening ceremony, Hyoung-Ki Kim, CEO and Vice Chairman of Celltrion, said, “The
opening our new UK office marks a pivotal milestone in Celltrion UK history. This demonstrates our
strong commitment to the UK, a strategic market for our growth. We are here for the long term and
are invested in the future of biosimilars in the UK. We look forward to continued collaboration with
local institutions and regulatory bodies to ensure sustainable access to high-quality biologic
treatments.”
Rosalind Campion, Director of the Office for Life Sciences, added, “With the NHS prescribing already
80% generic by volume, the next frontier is Biosimilars. This is a pivotal time for the sector just
before the introduction of the life sciences sector plan and the NHS 10 year plan”.
Mark Samuels, chief executive of Medicines UK, said, “Celltrion’s medicines are a critical part of the
UK life sciences ecosystem, and I am delighted that the company is strengthening its investment in
the UK with a new office, supporting British jobs and the supply of essential medicines for the NHS.”
The new headquarters also reflects continued growth for Celltrion UK, which has expanded its
headcount by 20% over the past year. With an exciting pipeline of new products spanning across
multiple therapeutic areas including allergy, endocrinology, ophthalmology and immunology
anticipated over the coming years, the company expects further recruitment and investment in the
coming years.
About Celltrion
Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us
About Celltrion Healthcare UK Limited (Celltrion UK)
Celltrion UK is committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the Medicines and Healthcare products Regulatory Agency (MHRA) regulations. For more information, please visit: www.celltrionhealthcare.co.uk/
